Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

NCT07169682 · clinicaltrials.gov ↗

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis
Cardiovascular Disease
Atherosclerosis

Interventions

DRUG: interleukin 17 inhibitor
DRUG: interleukin-23 inhibitor
DRUG: conventional systemic agent or apremilast

Sponsor

National and Kapodistrian University of Athens

Collaborators

[object Object]